Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review

By afschroeder • April 5, 2026

Armstrong AW, Krueger JG, Strober BE, Stein Gold LF, Desai SR, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley MK, Blauvelt A. Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review. Dermatol Ther (Heidelb). 2026 Apr 4. doi: 10.1007/s13555-026-01727-9. Epub ahead of print. PMID: 41934538.

Tags: autoimmune disease, Dermatology, envudeucitinib, ESK-001, Next-generation oral, psoriasis, Publications, TYK2

Related Posts

Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings

Maul JT, Fröhlich F, Nielsen ML, Maul LV, Torres T, Thyssen J, Armstrong A, Oon HH, Ji M, Kang X, Valenzuela F, Romiti R, Carvalho[...]

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib[...]

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani[...]